Coherus Oncology, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market Information Our common stock has been listed on The Nasdaq Global Market under the symbol “CHRS” since November 6, 2014. As of February 28, 2026, there were approximately 82 stockholders of record of our common stock. Dividends We have never declared or paid any cash dividends on our capital stock and do not anticipate paying cash dividends in the foreseeable future. Stock Performance Graph We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and in Item 10(f)(1) of Regulation S-K, therefore this disclosure item is not applicable. Recent Sales of Unregistered Equity Securities On October 20, 2025, the Company entered into a securities purchase agreement with certain accredited investors pursuant to which the Company sold to the investors: (i) an aggregate of 4,634,995 shares of the Company’s common stock, par value $0.0001 per share (the “PIPE Shares”), and (ii) warrants (the “PIPE Warrants”) to purchase an aggregate of 463,498 shares of common stock, for an aggregate purchase price of approximately $8.0 million. The purchase price for each PIPE Share, inclusive of a PIPE Warrant, was $1.726. Each PIPE Warrant entitles the holder to purchase shares of common stock at an exercise price of $0.01 per share, subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company’s common stock. The PIPE Warrants are exercisable at any time on or after the date of issuance and on or prior to October 21, 2030. As of December 31, 2025, no PIPE Warrants had been exercised. The PIPE Shares and the PIPE Warrants were offered and sold in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended. Each investor represented to the Company that it was an “accredited investor” as defined in Rule 501(a) of Regulation D under the Securities Act. No placement agent or underwriter was engaged in connection with the Private Placement. The Company reimbursed Bering Partners III, L.P. for $25,000 in legal fees incurred in connection with the Private Placement. Issuer Purchases of Equity Securities We did not repurchase any of our equity securities during the fourth quarter ended December 31, 2025. A total of 0 shares were surrendered to Coherus in the fourth quarter of 2025, to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards . ​ Item 6. [Reserved] 62 Table of Contents